Login / Signup

Adding vitamin D3 to the dipeptidyl peptidase-4 inhibitor saxagliptin has the potential to protect β-cell function in LADA patients: A 1-year pilot study.

Ziwei ZhangXiang YanChao WuXieyi PeiXia LiXiangbing WangXiaohong NiuHongwei JiangXiaomin ZengZhiguang Zhou
Published in: Diabetes/metabolism research and reviews (2020)
The data suggested that adding 2000 IU/day vitamin D3 to saxagliptin might preserve β-cell function in patients with LADA.
Keyphrases
  • end stage renal disease
  • newly diagnosed
  • chronic kidney disease
  • ejection fraction
  • prognostic factors
  • peritoneal dialysis
  • electronic health record
  • big data
  • risk assessment
  • deep learning
  • human health